AR130077A1 - Substratos escindibles por proteasas, y métodos de uso de los mismos - Google Patents
Substratos escindibles por proteasas, y métodos de uso de los mismosInfo
- Publication number
- AR130077A1 AR130077A1 ARP230102011A ARP230102011A AR130077A1 AR 130077 A1 AR130077 A1 AR 130077A1 AR P230102011 A ARP230102011 A AR P230102011A AR P230102011 A ARP230102011 A AR P230102011A AR 130077 A1 AR130077 A1 AR 130077A1
- Authority
- AR
- Argentina
- Prior art keywords
- cleavable
- protease
- seq
- substrate
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/2408—Membrane-type matrix metalloproteinase-1 (3.4.24.80)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se divulgan polipéptidos aislados que incluyen un resto escindible que es substrato para al menos una proteasa (por ej., MT-SP1 y/o una MMP) y polipéptidos aislados que incluyen un substrato que tiene un primer resto escindible que es escindible por una primera proteasa y un segundo resto escindible que es escindible por una segunda proteasa. Se divulgan moléculas activables que incluyen los polipéptidos aislados. Se divulgan métodos para preparar y usar los polipéptidos aislados y las moléculas activables que incluyen los polipéptidos aislados en una variedad de aplicaciones terapéuticas, de diagnóstico y profilácticas. Reivindicación 1: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende un primer resto escindible (CM1) que es escindible por al menos una primera proteasa, y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el CM1 comprende la secuencia de aminoácidos de PXGL, en donde X es W, Y, F, R, K, Q, A, o M, opcionalmente en donde el CM1 comprende la secuencia de aminoácidos de PXGL, en donde X es W, Y, F, R, K, Q, o M. Reivindicación 57: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende: APRG (SEQ ID Nº 382), o un primer resto escindible (CM1) que escindible por una primera proteasa y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el substrato comprende un núcleo APR y el substrato comprende la secuencia de aminoácidos de APRSL (SEQ ID Nº 669), APRSY (SEQ ID Nº 39), APRSM (SEQ ID Nº 383), APRGL (SEQ ID Nº 672), APRGY (SEQ ID Nº 384), o APRGM (SEQ ID Nº 385). Reivindicación 89: Un polipéptido aislado que comprende un substrato escindible por una MMP y una serina proteasa, caracterizado porque el substrato comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 695, opcionalmente en donde el substrato comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 683. Reivindicación 90: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende un primer resto escindible (CM1) que es escindible por una primera proteasa, y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el substrato comprende una secuencia de aminoácidos con una o más mutaciones de un aminoácido o dos aminoácidos de una cualquiera de las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 695, opcionalmente en donde el substrato comprende una secuencia de aminoácidos con una o más mutaciones de uno o dos aminoácidos de cualquiera de las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 683. Reivindicación 91: Un polipéptido aislado que comprende un resto escindible (CM) caracterizado porque comprende una secuencia de aminoácidos con una o más mutaciones de uno o dos aminoácidos de cualquiera de las SEQ ID Nº 382, en donde el CM es un substrato para una proteasa. Reivindicación 115: El método de la reivindicación 114, caracterizado porque la enfermedad es cáncer, una infección, un trastorno inflamatorio, un trastorno cardiovascular, un trastorno neurodegenerativo o un trastorno autoinmunitario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370026P | 2022-08-01 | 2022-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130077A1 true AR130077A1 (es) | 2024-10-30 |
Family
ID=87801206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102011A AR130077A1 (es) | 2022-08-01 | 2023-07-31 | Substratos escindibles por proteasas, y métodos de uso de los mismos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250215095A1 (es) |
| EP (1) | EP4565250A1 (es) |
| JP (1) | JP2025525754A (es) |
| AR (1) | AR130077A1 (es) |
| TW (1) | TW202424183A (es) |
| WO (1) | WO2024030850A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| CN119241656B (zh) * | 2024-12-09 | 2025-04-18 | 青岛农业大学 | 小分子活性肽、组合物及其在制备具有抗氧化降血糖功效的产品中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| WO2010006060A2 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| WO2010129609A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| SG178602A1 (en) | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR20140015139A (ko) | 2009-10-15 | 2014-02-06 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| NZ756892A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| IL317045A (en) | 2014-01-31 | 2025-01-01 | Cytomx Therapeutics Inc | Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| KR20170135860A (ko) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법 |
| EP3292150B1 (en) | 2015-05-04 | 2020-02-05 | Cytomx Therapeutics Inc. | Activatable anti-cd166 antibodies, and methods of use thereof |
| JP2018520092A (ja) | 2015-05-04 | 2018-07-26 | サイトメックス セラピューティクス インコーポレイテッド | 抗ＩＴＧａ３抗体、活性化可能抗ＩＴＧａ３抗体、およびその使用方法 |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| EA201890285A1 (ru) | 2015-07-13 | 2018-08-31 | Сайтомкс Терапьютикс, Инк. | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения |
| BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
| EP3592775A1 (en) | 2017-03-09 | 2020-01-15 | CytomX Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| BR112020000766A2 (pt) | 2017-07-14 | 2020-07-21 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 e seus usos |
| US12498367B2 (en) | 2017-07-20 | 2025-12-16 | Cytomx Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
| EP3676293A1 (en) | 2017-08-30 | 2020-07-08 | CytomX Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
| IL321773A (en) | 2017-10-14 | 2025-08-01 | Cytomx Therapeutics Inc | Activatable antibodies and methods for preparing them |
| US20200405890A1 (en) | 2018-02-21 | 2020-12-31 | Cytomx Therapeutics, Inc. | Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof |
| WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| WO2019213444A1 (en) | 2018-05-02 | 2019-11-07 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| JP2022512920A (ja) | 2018-11-02 | 2022-02-07 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗ｃｄ１６６抗体およびその使用方法 |
| CN120248140A (zh) | 2018-12-06 | 2025-07-04 | 西托姆克斯治疗公司 | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 |
| WO2020176672A1 (en) | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
| WO2020236679A1 (en) | 2019-05-17 | 2020-11-26 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| JP2022536511A (ja) | 2019-06-13 | 2022-08-17 | シートムエックス セラピューティクス，インコーポレイテッド | 癌の処置のための併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 |
| JP2022537151A (ja) | 2019-06-13 | 2022-08-24 | シートムエックス セラピューティクス，インコーポレイテッド | 癌の処置のためのネオアジュバント併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 |
| CN114650844A (zh) | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | 抗cd47抗体、可活化抗cd47抗体及其使用方法 |
| MX2022008381A (es) | 2020-01-06 | 2022-08-08 | Cytomx Therapeutics Inc | Compuestos relacionados con auristatina, compuestos conjugados de auristatina y metodos de uso de ellos. |
| EP4132656A1 (en) | 2020-04-09 | 2023-02-15 | CytomX Therapeutics, Inc. | Compositions containing activatable antibodies |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
-
2023
- 2023-07-31 AR ARP230102011A patent/AR130077A1/es unknown
- 2023-07-31 JP JP2025503386A patent/JP2025525754A/ja active Pending
- 2023-07-31 TW TW112128640A patent/TW202424183A/zh unknown
- 2023-07-31 WO PCT/US2023/071310 patent/WO2024030850A1/en not_active Ceased
- 2023-07-31 EP EP23761347.6A patent/EP4565250A1/en active Pending
-
2025
- 2025-03-17 US US19/081,340 patent/US20250215095A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024030850A1 (en) | 2024-02-08 |
| EP4565250A1 (en) | 2025-06-11 |
| JP2025525754A (ja) | 2025-08-07 |
| TW202424183A (zh) | 2024-06-16 |
| US20250215095A1 (en) | 2025-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130077A1 (es) | Substratos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130079A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130076A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130080A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| CO2022008004A2 (es) | Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos | |
| PE20010694A1 (es) | Plasmido autonomamente reproducible en bacterias corineformes | |
| CO2021009695A2 (es) | Conjugados de il-2 y métodos de uso de este | |
| ATE440611T1 (de) | Virale vektoren | |
| MX2022014411A (es) | Polipéptidos il-12 activables y métodos de uso de estos. | |
| AR118668A1 (es) | Composiciones para editar genoma a base de crispr / cas para restaurar la función de distrofina | |
| AR062300A2 (es) | Polipeptido que comprende una porcion inmunogenica de una proteina de prostata o su variante, molecula de adn, vector de expresion, celula huesped composicion farmaceutica, vacuna uso de dichas composiciones y vacunas para preparar medicamentos y proteina de fusion | |
| ES2174097T3 (es) | Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma. | |
| CY1109779T1 (el) | Αναστολεις της hcv ns-3 πρωτεασης σερινης | |
| BRPI0607988A2 (pt) | composto, composição farmacêutica, e método para induzir apoptose em uma célula | |
| CO6251278A2 (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol | |
| DK0382403T3 (da) | Ekspressionssystemer til et amiderende enzym | |
| CY1114526T1 (el) | Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων | |
| ZA202501953B (en) | Masking polypeptide, activatable novel prodrugs and methods of use thereof | |
| AR130640A1 (es) | Polipéptidos activados con proteasa | |
| MX9704575A (es) | Compuestos quimicos. | |
| NO991995L (no) | Nukleinsyre- og aminosyresekvenser relatert til Heliobacter pylori og vaksinesammensetninger derav | |
| Zhu et al. | Developing novel activity-based fluorescent probes that target different classes of proteases | |
| ES2149837T3 (es) | Vector recombinante para la preparacion exocelular de anticuerpos monocatenarios expresados en bacillus subtilis. | |
| AR241713A1 (es) | Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe. | |
| PT672157E (pt) | Virus recombinantes de local de clivagem proteolitica artificial |